Journey Medical Rides Emrosi Surge Toward Profitability

Journey Medical Corporation ((DERM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Journey Medical Corporation’s latest earnings call struck an optimistic tone, as management highlighted a strong commercial ramp for Emrosi, expanding margins and a swing to positive adjusted EBITDA. Executives acknowledged ongoing headwinds from payer dynamics, generic pressure and higher spending, yet framed these as manageable risks against clear momentum toward sustainable profitability.

Emrosi Launch Drives Prescription and Revenue Momentum

Emrosi anchored the call, delivering $14.7 million in net sales over the three quarters it was on the market in 2025 and roughly 53,000 prescriptions since promotion began in April. Fourth‑quarter scripts jumped nearly 50% sequentially, implying an annualized run rate above 126,000 prescriptions and growing prescriber adoption from about 3,200 to more than 3,500.

Top-Line Expansion Supported by New Product Uptake

Total 2025 revenue climbed 10% to $61.9 million from $56.1 million in 2024, with Emrosi’s contribution offsetting erosion in older brands. Management stressed that net product revenue rose 11%, underlining that the growth is not just volume-driven but reflects a healthier mix despite pressure in the Accutane franchise.

Margin Expansion Signals Healthier Product Mix

Gross margin improved to 66.2% in 2025 from 62.8% a year earlier, a gain of roughly 3.4 percentage points that management tied to Emrosi and QBREXZA. Lower inventory period costs also helped, suggesting the company is not only selling more but keeping a greater share of each dollar as its newer products scale.

Steady March Toward Profitability

Adjusted EBITDA turned positive at $2.9 million in 2025 versus $0.8 million in 2024, while EBITDA losses narrowed by $5.2 million to $4.0 million. Importantly, Journey posted both positive EBITDA and positive adjusted EBITDA in the fourth quarter, reinforcing management’s message that the model is inflecting toward sustained profitability.

Balance Sheet and Working Capital Strengthen

Cash ended 2025 at $24.1 million, up from $20.3 million a year earlier, while working capital nearly doubled to $29.4 million from $13.0 million. Management framed this as a stronger financial foundation to support launches and sales-force investments, though they cautioned that near-term receivables timing could influence cash flow.

Clinical and Third-Party Endorsements Bolster Emrosi

Emrosi’s Phase III data showing superiority versus Oracea were published in JAMA Dermatology, and the National Rosacea Society updated its treatment algorithms to include the therapy. Journey expects two to three additional publications this year, with executives emphasizing that such external validation helps drive prescriber confidence and payer acceptance.

Market Access and Coverage Continue to Expand

Contracting with two of the top three group purchasing organizations gives Emrosi access to about 100 million commercial covered lives, with a third large GPO expected to follow. Management said this could expand framework access toward roughly 150 million lives, improving reimbursement dynamics and reducing dependence on co‑pay support over time.

Patient Retention Trends Turn More Favorable

Refill behavior is strengthening, with the refill ratio rising from about 1.0 refill per new prescription in the third quarter to roughly 1.4 in the fourth quarter. Executives cited this as an indicator of patient satisfaction and durability of use, which could translate into higher lifetime revenue per patient as the base of treated patients grows.

Plans for Targeted Portfolio Expansion

Journey intends to launch one to two additional niche dermatology products in 2026, leveraging its existing commercial infrastructure rather than building from scratch. Management believes these bolt-on launches can augment the base business and diversify revenue while keeping incremental sales and marketing costs relatively efficient.

Legacy Portfolio Faces Generic Headwinds

The Accutane franchise and other legacy products continued to face generic competition, with management pointing to about $6.5 million of revenue regression in Accutane alone. This erosion weighed on the base business, reinforcing why the company is pushing newer brands and pipeline additions to offset generic-driven declines.

GAAP Loss Narrows but Remains Material

Journey still reported a GAAP net loss of $11.4 million, or $0.47 per share, in 2025, though this improved from a $14.7 million loss, or $0.72 per share, in 2024. Management framed the roughly 22% reduction as meaningful progress, yet investors are reminded that the path to full GAAP profitability remains incomplete.

Revenue-per-Script Variability Clouds Visibility

Analysts flagged notable swings in revenue per Emrosi prescription, with cited quarter-by-quarter estimates ranging from about $380 down to roughly $180. Management argued that the fourth-quarter figure is not representative, pointing instead to a 2025 average around $280 while acknowledging that gross-to-net remains sensitive to payer mix and co‑pay assistance.

Payer Timing Lags Delay Revenue Conversion

Executives noted that Emrosi prescription demand is running ahead of recognized revenue because of health-plan coverage cycles, new-to-market moratoriums and formulary rollout timing. These factors create delays between script generation and revenue capture, adding noise to quarterly numbers even as underlying demand trends remain strong.

Higher Operating Expenses and Sales Expansion Plans

Selling, general and administrative expenses rose about 10% to $44.4 million in 2025, reflecting launch-related investments behind Emrosi. Looking ahead, management plans a single-digit increase in sales headcount by early third quarter 2026, which will lift near-term operating expenses but is expected to support further top-line growth.

Receivables and Near-Term Cash Timing Risks

A notable build in accounts receivable during the fourth quarter raised questions about cash conversion, which management attributed primarily to order timing. While they do not see structural issues, executives conceded that this dynamic could modestly affect cash collections in early 2026, adding some short-term uncertainty around liquidity trends.

Short-Term Prescription Volatility Masks Underlying Trend

The company described first-quarter 2026 prescription patterns as “flattish,” citing deductible resets, adverse weather and shorter months as temporary drags. Management expects momentum to recover in March and more clearly in the second quarter, though they cautioned that such seasonal swings make precise quarter-to-quarter forecasting more challenging.

Guidance and Outlook Emphasize Sustained EBITDA Positivity

Management guided to remaining adjusted EBITDA positive in 2026 and beyond, underpinned by Emrosi’s growing script base, better reimbursement and expanding market access. They anticipate gradual improvement in gross-to-net, reduced co‑pay reliance, a meaningful revenue inflection as formularies mature, modest sales-force growth and one to two additional dermatology launches, with more detailed financial targets to follow as payer adoption solidifies.

Journey Medical’s earnings call painted the picture of a dermatology specialist shifting from turnaround to growth mode, powered by Emrosi’s rapid uptake and margin expansion. While GAAP losses, generic headwinds and reimbursement complexity still weigh on the story, management’s confidence in sustained adjusted EBITDA profitability and a broader product platform offers investors a cautiously constructive setup for 2026.